Patents Assigned to Bayer Healthcare AG
  • Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors
    Publication number: 20060241127
    Abstract: The invention relates to heteroaryloxy-substituted phenylaminopyrimidines, to methods for the production thereof, and to the use of the same for producing medicaments for the treatment and/or prophylaxis of diseases, especially cardiovascular diseases. The inventive compounds inhibit Rho-Kinase.
    Type: Application
    Filed: October 16, 2003
    Publication date: October 26, 2006
    Applicant: BAYER HEALTHCARE AG
    Inventors: Achim Feurer, Samir Bennabi, Heike Heckroth, Hartmut Schirok, Joachim Mittendorf, Raimund Kast, Johannes-Peter Stasch, Jean Gnoth, Klaus Munter, Dieter Lang, Santiago Perez, Heimo Ehmke
  • Diagnostics and therapeutics for diseases associated with bile acid g-protein-coupled receptor 37 (bg37)
    Publication number: 20060240013
    Abstract: The invention provides a human BG37 which is associated with the disorders of the gastroenterology system, disorders of the peripheral and central nervous system, urology diseases, hematology diseases, cancer diseases, inflammation and cardiovascular diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of disorders of the gastroenterology system, disorders of the peripheral and central nervous system, urology diseases, hematology diseases, cancer diseases, inflammation and cardiovascular diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of BG37 as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: November 11, 2003
    Publication date: October 26, 2006
    Applicant: BAYER HEALTHCARE AG
    Inventors: Stefan Golz, Ulf Bruggemeier, Holger Summer
  • Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine 1f receptor (5-ht1f)
    Publication number: 20060234240
    Abstract: The invention provides a human 5-HT1F which is associated with the hematological diseases, disorders of the peripheral and central nervous system, gastrointestinal diseases, cardiovascular diseases, cancer, muscle/skeleton disorders, respiratory diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of hematological diseases, disorders of the peripheral and central nervous system, gastrointestinal diseases, cardiovascular diseases, cancer, muscle/skeleton disorders, respiratory diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of 5-HT1F as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: February 4, 2004
    Publication date: October 19, 2006
    Applicant: Bayer HealthCare AG
    Inventors: Stefan Golz, Ulf Brüggemeier, Andreas Geerts
  • Novel uses of parapoxvirus preparations
    Publication number: 20060233833
    Abstract: The present invention related to use of Parapoxvirus preparations for the treatment of conditions related to infections with strictly intracellular bacteria
    Type: Application
    Filed: May 23, 2003
    Publication date: October 19, 2006
    Applicant: BAYER HEALTHCARE AG
    Inventors: Hans-Robert Hehnen, Bernhard Kaltenboeck, Tobias Schlapp
  • 2-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
    Patent number: 7122540
    Abstract: The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.
    Type: Grant
    Filed: August 20, 2004
    Date of Patent: October 17, 2006
    Assignee: Bayer HealthCare AG
    Inventors: Maria Niewöhner, legal representative, Mazen Es-Sayed, Helmut Haning, Thomas Schenke, Karl-Heinz Schlemmer, Jörg Keldenich, Erwin Bischoff, Elisabeth Perzborn, Klaus Dembowsky, Peter Semo, Marc Nowakowski, Ulrich Niewöhner, deceased
  • Hetrocyclic aryl sulphonamides
    Patent number: 7115636
    Abstract: The invention relates to novel sulfonamides of general formula (I) where the substituents R1, R2, R3, R4, A and X have the given meanings, pharmaceutical compositions containing them, and a method of using them as antiviral agents, in particular against cytomegaloviruses.
    Type: Grant
    Filed: July 24, 2002
    Date of Patent: October 3, 2006
    Assignee: Bayer Healthcare AG
    Inventors: Tobias Wunberg, Wolfgang Bender, Peter Eckenberg, Sabine Hallenberger, Kerstin Henninger, Jörg Keldenich, Armin Kern, Siegfried Raddatz, Jürgen Reefschläger, Gunter Schmidt, Holger Zimmermann, Franz Zumpe, Martin Radtke
  • Cloning and characterization of a human adenylyl cyclase
    Patent number: 7115570
    Abstract: A DNA sequence encoding a human adenylyl cyclase is described. The amino acid sequence of the adenylyl cyclase is also described.
    Type: Grant
    Filed: November 17, 2004
    Date of Patent: October 3, 2006
    Assignee: Bayer Healthcare AG
    Inventor: James E. Tomlinson
  • Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same
    Publication number: 20060217373
    Abstract: Compounds of the formula (I) a process for their preparation and their use as medicaments are described.
    Type: Application
    Filed: May 30, 2006
    Publication date: September 28, 2006
    Applicant: Bayer Healthcare AG
    Inventors: Ulrich Rosentreter, Thomas Kramer, Mitsuyuki Shimada, Walter Hubsch, Nicole Diedrichs, Thomas Krahn, Kerstin Henninger, Johannes-Peter Stasch, Ralf Wischnat
  • Diagnostics and therapeutics for diseases associated with g-protein coupled protease activated receptor 1 (Par1)
    Publication number: 20060216290
    Abstract: The invention provides a human PAR1 which is associated with the cardiovascular disorders, dermatological disorders, orders, gastrointestinal and liver diseases, neurological disorders, cancer disorders and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, dermatological disorders, gastrointestinal and liver diseases, neurological disorders, cancer disorders and urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of PAR1 as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: February 26, 2004
    Publication date: September 28, 2006
    Applicant: BAYER HEALTHCARE AG
    Inventors: Stefan Golz, Holger Summer
  • Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same
    Patent number: 7109218
    Abstract: Compounds of the formula (I) a process for their preparation and their use as medicaments are described.
    Type: Grant
    Filed: November 28, 2002
    Date of Patent: September 19, 2006
    Assignee: Bayer HealthCare AG
    Inventors: Ulrich Rosentreter, Thomas Krämer, Mitsuyuki Shimada, Walter Hübsch, Nicole Diedrichs, Thomas Krahn, Kerstin Henninger, Johannes-Peter Stasch, Ralf Wischnat
  • Homogeneous fluorescence assay for kinases, phosphatases, and phosphodiesterases
    Publication number: 20060188952
    Abstract: The present invention relates to a homogeneous assay method of quantitative measurement of kinase, phosphatase and phosphodiesterase (PDE) reactions. The method may be used both in a direct and in a competitive assay format.
    Type: Application
    Filed: August 18, 2003
    Publication date: August 24, 2006
    Applicant: Bayer HealthCare AG
    Inventor: Franz-Josef Meyer-Almes
  • Diagnostics and therapeutics for diseases associated with phosphodi-esterase 1c (pde1c)
    Publication number: 20060188882
    Abstract: The invention provides a human PDE1C which is associated with the cardiovascular disorders, gastrointestinal and liver diseases, cancer disorders, neurological disorders, respiratory Diseases and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, gastrointestinal and liver diseases, cancer disorders, neurological disorders, respiratory Diseases and urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of PDE1C as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: February 27, 2004
    Publication date: August 24, 2006
    Applicant: BAYER HEALTHCARE AG
    Inventors: Stefan Golz, Ulf Bruggemeier, Andreas Geerts
  • Modulators of the potassium channels twik-1, task-1 gorl1. sk2 pr pcn1, used to treat arrhythmia, coronary heat disease or hypertension
    Publication number: 20060183665
    Abstract: The invention relates to the use of modulators of the potassium channels TWIK-1, TASK-1, GIRK1 SK2 and PCN1 for producing a medicament for the treatment and/or prophylaxis of cardiac dysrhythmias (arrhythmias), coronary heart disease, and hypertension.
    Type: Application
    Filed: July 6, 2004
    Publication date: August 17, 2006
    Applicant: Bayer HealthCare AG
    Inventors: Peter Ellinghaus, Klaus Munter
  • Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
    Publication number: 20060183753
    Abstract: The present invention relates to the use of 2,5-diamidoindole derivatives for the preparation of medicaments for treating urological disorders in humans and/or animals.
    Type: Application
    Filed: December 6, 2003
    Publication date: August 17, 2006
    Applicant: Bayer HealthCare AG
    Inventors: Jens Erguden, Thomas Krahn, Christian Schroder, Johannes Stasch, Stefan Weigand, Hanno Wild, Michael Brands, Stehan Siegel, Dirk Heimbach, Jorg Keldenich, Masaomi Tajimi, Hiroko Takagi
  • 2,5-disubstituted pyrimidine derivatives
    Patent number: 7091198
    Abstract: The present invention relates to novel 2,5-disubstituted pyrimidine derivatives which stimulate soluble guanylate cyclase, to processes for the preparation thereof, and to the use thereof for producing medicaments, in particular medicaments for the treatment of central nervous system diseases.
    Type: Grant
    Filed: July 7, 2003
    Date of Patent: August 15, 2006
    Assignee: Bayer HealthCare AG
    Inventors: Achim Feurer, Joachim Luithle, Stephan-Nicholas Wirtz, Gerhard König, Johannes-Peter Stasch, Elke Stahl, Rudy Schreiber, Frank Wunder
  • Imidazo[1,3,5]triazinones and their use
    Patent number: 7091203
    Abstract: The invention relates to imidazo[1,3,5]triazinones, a method for their production and methods of use, in particular as inhibitors of cyclic GMP metabolizing phosphodiesterases.
    Type: Grant
    Filed: July 15, 2004
    Date of Patent: August 15, 2006
    Assignee: Bayer Healthcare AG
    Inventors: Ulrich Niewöhner, Helmut Haning, Thomas Lampe, Mazen Es-Sayed, Gunter Schmidt, Erwin Bischoff, Klaus Dembowsky, Elisabeth Perzborn, Karl-Heinz Schlemmer
  • Arylamides
    Publication number: 20060173040
    Abstract: The present invention relates to compounds, to processes for preparing them, to pharmaceutical compositions comprising them, and to their use in the therapy and/or prophylaxis of diseases in people or animals, especially diseases of bacterial infection.
    Type: Application
    Filed: July 28, 2003
    Publication date: August 3, 2006
    Applicant: Bayer HealthCare AG
    Inventors: Nina Brunner, Christoph Freiberg, Thomas Lampe, Peter Nell, Ben Newton, Michael Otteneder, Josef Pernerstorfer, Jens Pohlmann, Guido Schiffer, Mitsuyuki Shimada, Niels Svenstrup, Rainer Endermann
  • Diagnostics and therapeutics for diseases associated with human phosphodiesterase 11a (pde11a)
    Publication number: 20060166911
    Abstract: The invention provides a human PDE11A which is associated with the disorders of the peripheral and central nervous system, cardiovascular diseases, cancer, liver disease and genito-urinary diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of disorders of the peripheral and central nervous system, cardiovascular diseases, cancer, liver disease and genito-urinary diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of PDE11A as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: September 18, 2003
    Publication date: July 27, 2006
    Applicant: Bayer Healthcare AG
    Inventors: Stefan Golz, Ulf Bruggemeier, Andreas Geerts
  • 2-naphthamide derivatives
    Publication number: 20060166989
    Abstract: The present invention relates to 2-naphthamides, which are useful as an active ingredient of pharmaceutical preparations. The 2-naphthamides of the present invention have IP receptor antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with IP receptor activity. Such diseases include urological diseases or disorder as follows: bladder outlet obstruction, overactive bladder, urinary incontinence, detrusor hyper-reflexia, detrusor instability, reduced bladder capacity, frequency of micturition, urge incontinence, stress incontinence, bladder hyperreactivity, benign prostatic hypertrophy (BPH), pro-statitis, urinary frequency, nocturia, urinary urgency, pelvic hypersensitivity, urethritis, pelvic pain syndrome, prostatodynia, cystitis, or idiophatic bladder hypersensitivity.
    Type: Application
    Filed: May 30, 2003
    Publication date: July 27, 2006
    Applicant: Bayer Healthcare AG
    Inventors: Makoto Shimazaki, Osamu Sakurai, Toshiki Murata, Klaus Urbahns, Noriyuki Yamamoto, Satoru Yoshikawa, Masaomi Umeda, Masaomi Tajimi, Tsutomu Masuda, Takuya Shintani, Haruka Shimizu
  • Diagnostics and therapeutics for diseases associated with vasoactive intestinal peptide receptor 2 (vpac2)
    Publication number: 20060165679
    Abstract: The invention provides a human VPAC2 which is associated with the disorders of the peripheral and central nervous system, cardiovascular diseases, hematological diseases, genitourinary diseases, inflammation. The invention also provides assays for the identification of compounds useful in the treatment or prevention of disorders of the peripheral and central nervous system, cardio-vascular diseases, hematological diseases, genitourinary diseases, inflammation. The invention also features compounds which bind to and/or activate or inhibit the activity of VPAC2 as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: April 25, 2003
    Publication date: July 27, 2006
    Applicant: Bayer HealthCare AG
    Inventors: Stefan Golz, Ulf Bruggemeier, Holger Summer